Target intelligence / Profile preview

Caspase-3, Bad, Bax (N/A)

Target
N/A
Molecular classification
Enzyme, Protease, Cysteine-aspartic protease, Executioner caspase, Regulatory protein, Pro-apoptotic Bcl-2 family member, BH3-only protein
01

Overview

This entry incorrectly groups three distinct molecular targets: Caspase-3, Bad, and Bax. Caspase-3 is a cysteine-aspartic protease and key executioner in apoptosis. Bad is a pro-apoptotic BH3-only protein that antagonizes anti-apoptotic Bcl-2 proteins. Bax is a key pro-apoptotic Bcl-2 family member that facilitates mitochondrial outer membrane permeabilization. While all three are involved in the apoptosis pathway and are recognized therapeutic targets, they represent independent gene products, structures, specific functions, and have distinct therapeutic implications. They should be catalogued individually for biomedical or drug discovery purposes.

02

Mechanism of action

This entry comprises three distinct proteins with varied mechanisms of action. Caspase-3 acts as an executioner protease leading to programmed cell death. BAD promotes apoptosis by neutralizing anti-apoptotic Bcl-2 proteins. BAX promotes mitochondrial permeabilization and cytochrome c release, leading to caspase activation. Each plays a distinct role within the apoptosis pathway.

03

Biological functions

ApoptosisCell deathCleavage of cellular proteinsDNA fragmentationImmune regulationNon-apoptotic roles (e.g. neuron homeostasis)Apoptosis initiationRegulation of mitochondrial outer membrane permeabilizationModulation of cell survival pathwaysSynaptic plasticityRelease of cytochrome cRegulation of cell death and survival
04

Disease associations

CancerNeurodegenerative diseaseIschemia-reperfusion injuryInflammatory diseasesOther diseases involving apoptosis dysregulationIschemic injury
05

Safety considerations

Systemic inhibition of caspases may interfere with physiological cell turnover; overactivation leads to excessive cell loss.Non-specific targeting of BAD may impact normal tissue homeostasis, leading to toxicity.Excess activation of BAX kills normal cells, while inhibition may allow tumor cell survival.
06

Interacting drugs

Z-DEVD-FMK (caspase inhibitor)

6 more in the full profile.

07

Biomarkers

Cleaved caspase-3 (indicator of apoptosis)Altered BAD phosphorylation status (apoptosis marker)Bax expression (readout for pro-apoptotic potential in tissues and tumors)

Beyond the preview

Go deeper on Caspase-3, Bad, Bax (N/A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Caspase-3, Bad, Bax (N/A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call